Background/Aims: Considerable evidence indicates that long noncoding RNAs (lncRNAs) exert importantly regulatory functions during human cancer initiation and progression and are promising biotargets in the fight against cancer. Methods: In this study, we evaluated the role of the lncRNA LINC01133 in esophageal squamous cell carcinoma (ESCC). LINC01133 expression in ESCC was examined by quantitative real-time PCR. The correlations between LINC01133 expression and clinicopathological variables and survival were examined by the c 2 test, Kaplan-Meier method, log-rank test, and univariate Cox regression analysis. Results: LINC01133 expression levels were frequently lower in ESCC tissues and cell lines than in paired normal tissues and an immortalized esophageal epithelial cell line, respectively. The expression of LINC01133 decreased in a TNM stage-and lifestyle-independent manner. LINC01133 was an independent protective factor and had an anti-tumor effect in the early stage of ESCC development. More importantly, we discovered that drinking status in our cohort impaired the predictive accuracy of LINC01133 for patients with ESCC. Furthermore, a new risk model combining LINC01133 expression, drinking status, and TNM stage provided better survival discrimination compared with three other predictors. Conclusions: Our data indicate that a loss of LINC01133 expression is a potential poor prognostic biomarker and therapeutic target for ESCC and provide additional prognostic information to improve the outcomes of ESCC patients.
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Introduction
Esophageal carcinoma (EC) is one of the most common cancers and a leading cause of cancer-related deaths according to the latest global and Chinese cancer statistics [1, 2] . Approximately 50% of EC cases occur in China, and 90% of cases are esophageal squamous cell carcinoma (ESCC), the predominant histological type of EC [3, 4] . The mortality rates of ESCC have begun to decline due to recent advances in diagnostic and therapeutic techniques, but the 5-year overall survival (OS) for patients with resectable ESCC is only 35-45%, which is still dismal [5, 6] . This can likely be explained by the inability of the TNM staging system to accurately predict the prognosis of patients with resectable ESCC [7] . Some patients with early-stage ESCC rapidly develop local and regional recurrences and distant metastases after esophagectomy [8] . Therefore, it is imperative to identify novel prognostic biomarkers to assist oncologists in improving the predictive accuracy of the TNM staging system for ESCC.
Over the past decade, long noncoding RNAs (lncRNAs) have attracted considerable research attention [9] . Although lncRNAs lack protein-coding capacity, they drive many critical biological processes, including tumor growth, invasion, and metastasis [10] [11] [12] . For instance, the lncRNA HOTAIR (HOX antisense intergenic RNA) is one of the most important oncogenic lncRNAs in several human tumor types, including breast cancer, hepatocellular carcinoma, and colorectal cancer [10] . HOTAIR regulates tumor proliferation, migration, and chemotherapeutic sensitivity by modulating gene expression and chromatin dynamics [13] . In addition, the lncRNA XIST (X-inactive specific transcript), involved in genetic imprinting, appears to be dysregulated in various cancers, including lung cancer, gastric cancer, and ESCC [4, 14, 15] . Owing to their powerful functions and tissue-specific expression, lncRNAs are considered highly promising biomarkers in cancer diagnosis, therapy, and prognosis [16] .
LINC01133 is a novel lncRNA located on human chromosome 1q23 that encodes a long intergenic noncoding RNA (Table 1) . High expression of LINC01133 was first reported in lung squamous cell cancer [17] . Knockdown of LINC01133 significantly inhibits the migration and invasion capacity of lung cancer cells and osteosarcoma cells by targeting EZH2, LSD1, and sponging miR-422a [18, 19] . Interestingly, two recent studies have shown that LINC01133 expression is lost in colorectal cancer, and the silencing of LINC01133 suppresses metastasis and epithelial-mesenchymal transition by interacting with SRSF6 [20, 21] . These contradictory results suggest that LINC01133 exerts both a positive and negative effect on migration and invasion in a tumor type-dependent manner. However, very little is known about the expression level and prognostic significance of LINC01133 in ESCC.
Materials and Methods
ESCC tissue specimens ESCC tissues and paired normal esophageal epithelial tissues from 149 patients were surgically collected at Sun Yat-Sen University Cancer Center between January 2007 and December 2009. The eligibility criteria for patients with ESCC were (1) no distant metastases and no local and/or systemic treatment before the operation, (2) histological diagnosis of samples by two pathologists, and (3) no serious complications or other malignant disease. The clinical stage was determined according to the 7th edition of the TNM classification of the International Union against Cancer (UICC). Overall survival (OS) was defined as the time from the date of radical surgery to the date of death or last follow-up, and progression-free survival (PFS) was the time from the date of radical surgery to the date of relapse, metastasis, or last follow-up. The study was reviewed and approved by the medical ethics committee of Sun Yat-Sen University Cancer Center. Informed consent was obtained from each patient before surgery. ) and an immortalized esophageal epithelial cell line, NE-1, were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). Cancer cells were cultured at 37°C and 5% CO 2 in RPMI-1640 medium (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum. The NE-1 cell line was maintained in a 1:1 mixture of defined keratinocyte serum-free medium with growth supplements (Gibco) and EpiLife medium (Cascade Biologics, Portland, OR). All experiments were performed during the exponential phase of cell growth.
Quantitative real-time PCR (qRT-PCR)
Total RNA from ESCC tissues and cells was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Total RNA quality and concentration were examined by absorbance at 260/280 nm using a NanoDrop-2000 spectrophotometer (NanoDrop Products, Wilmington, DE). RNA was reverse transcribed to cDNA using PrimeScript TM RT Master Mix (Takara, Dalian, China). For quantitative real-time PCR (qRT-PCR), the cDNA was quantified in triplicate using SYBR Green Mix (Promega, Madison, WI) on a Light Cycler 480 instrument (Roche, Basel, Switzerland). The relative expression of LINC01133 was calculated using the 2 −ΔΔCt method and GAPDH was used as the reference gene. The following primers were used for qRT-PCR. LINC01133 forward: 5′-TGGTGGAGAGAATGGAGG -3′; reverse: 5′-AACCCAGTTCCTTAGAATCTTC -3′. GAPDH forward: 5′-CTCCTCCTGTTCGACAGTCAGC -3′; reverse: 5′-CCCAATACGACCAAATCCGTT -3′.
Statistical analysis
All statistical analyses were implemented in SPSS version 23.0 (SPSS, Chicago, IL). Relative expression of LINC01133 in ESCC tissues and paired normal tissues was evaluated by the paired-sample t-test. The chi-squared test or Fisher's exact test was used to examine the correlation between LINC01133 expression and various clinicopathological variables. Survival analysis was performed using the Kaplan-Meier method, and the log-rank test was used to assess the differences between patient groups or subgroups. Univariate and multivariate Cox proportional hazards regression analyses were used to identify the independent prognostic factors that predict OS and PFS. All P-values were two-sided and P-values of less than 0.05 were defined as statistically significant.
Results

LINC01133 is expressed at low levels in ESCC tissues and cell lines
Given the important role of LINC01133 in the pathogenesis of several human cancers, we first examined its expression level in 149 pairs of ESCC tissues (T) and matched adjacent non-cancerous esophageal tissues (N) by qRT-PCR. We detected reduced expression of LINC01133 in the majority of ESCC tissues (P < 0.0001, Fig. 1A and 1B). LINC01133 expression was downregulated in 66.4% of tumor tissues, with 3-fold lower relative expression levels in tumors than in paired normal tissues (Fig. 1B) . We also examined LINC01133 expression in a panel of ESCC cell lines. Compared with the immortalized normal epithelial cell line NE-1, LINC01133 expression was generally lower in 6 of 9 ESCC cell lines (Fig. 1C) . These results indicate that LINC01133 was significantly downregulated in ESCC and imply that it functions as a tumor suppressor in ESCC.
Reduced expression of LINC01133 is positively correlated with cancer progression and unhealthy lifestyles in patients with ESCC
Next, we evaluated the relationship between LINC01133 expression and widely recognized clinicopathological features of ESCC patients. The clinicopathological and demographic data of our cohort are shown in Table 2 . These patients were divided into LINC01133 high-and low-expression groups according to their relative expression in ESCC tissues with the median cancer/normal fold change (0.512) as the cutoff value. Chi-squared analysis indicated that low LINC01133 expression in ESCC is remarkably associated with Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry ever smoking, ever drinking, large tumor size (≥5 cm in length), greater depth of tumor invasion (stage T3-T4), lymph node metastasis (stage N1-3), and advanced TNM stage (stage III) (all P < 0.05, Table 2 ). No significant statistical association was observed between LINC01133 expression and other clinicopathological variables ( Table 2) . We further assessed the relative expression of LINC01133 in different subgroups. LINC01133 expression decreased strikingly with increases in TNM stage, T stage, and N stage ( Fig. 2A-2C ). However, no statistically significant difference was found between stages T2 and T3, among stages N1, N2, and N3, and between tumors of different sizes (Fig. 2B-2D) . Surprisingly, although there was a marginally significant difference in expression between patients with different smoking statuses, LINC01133 was markedly lower in patients who reported ever drinking than in those who reported never drinking ( Fig. 2E and 2F ). Taken together, these results suggest that LINC01133 is intimately involved in cancer progression and is related to unhealthy lifestyles in patients with ESCC.
LINC01133 downregulation is associated with poor prognosis in ESCC
To evaluate the clinical significance of LINC01133 in this malignancy, we analyzed the correlation between clinicopathologic variables and clinical outcomes, including OS and PFS. Univariate analysis revealed that drinking status, T stage, N stage, TNM stage, and LINC01133 expression were significant prognostic factors for OS and PFS in ESCC patients (all P < 0.05, Table 3 ). Multivariate analysis indicated that LINC01133 is an independent favorable predictor of OS (HR: 0.459; 95% CI: 0.260-0.810; P = 0.007) and PFS (HR: 0.500; 95% CI: 
0.307-0.812; P = 0.005) for ESCC patients (Table 3) . Additionally, N stage was an independent predictor of poorer OS and PFS, and T stage was an independent predictor of only poorer OS in ESCC patients (Table 3) .
To further explore the predictive value of LINC01133, the log-rank test and KaplanMeier survival analysis were used to investigate the association between LINC01133 expression and prognosis in our patient cohort. The LINC01133 low-expression group had a significantly shorter 5-year OS rate (34.3% vs. 71.9%) and 5-year PFS rate (21.6% vs. 56.7%) compared with those in the LINC01133 high-expression group (all P < 0.0001, Fig.  3A) , suggesting that the underexpression of LINC01133 is significantly associated with poor prognosis in ESCC.
We further stratified the 149-patient cohort into subgroups according to tumor size, pathological grade, and TNM stage. LINC01133 maintained its predictive value for OS and PFS in all of the subgroups, excluding PFS in patients with tumor size ≥5 cm (P = 0.0683) or TNM stage III (P = 0.1032) (Fig. 3B-3G) . Interestingly, the discriminative power of LINC01133 was obviously stronger for patients with small tumors, pathological grade I-II, and TNM stage I-II than for patients with large tumors, grade III, and stage III (Fig. 3B-3G ). These observations suggest that LINC01133 is a novel prognostic marker for ESCC and could be implicated in the early stage of ESCC development. 
Prognostic significance of LINC01133 is influenced by drinking status in ESCC patients
Tobacco and alcohol use are major risk factors for ESCC [3] . Based on the negative correlation between LINC01133 expression and smoking or drinking status (Table 2 and Fig. 2) , patients with ESCC were stratified into two subgroups. A Kaplan-Meier survival analysis verified that LINC01133 maintained its independent prognostic value, irrespective of whether patients had smoked or not (Fig. 4A and 4B) , and similar results were observed in the patient subgroup stratified by drinking status (all P < 0.05) (Fig. 4C and 4D ). More interestingly, patients with low LINC01133 expression had similarly poor OS and PFS, regardless of their drinking status (all P > 0.05, Fig. 4E ). However, in the subgroup with high LINC01133 expression, patients who reported ever drinking had significantly shorter OS (P = 0.0261) and marginally significantly worse PFS (P = 0.0532) than those of patients between group 2 and group 3 (score 2) was not statistically significant (Fig. 5B) . In this case, group 2 and 3 were combined into a new group 1 (score 1). TNM stage I-II and stage III were scored 0 and 1, respectively. As illustrated in Fig. 5C , a new combined risk score was calculated as the sum of the scores for the new group (0 or 1) and TNM stage (0 or 1) for each case. Patients with combined scores of 0, 1, or 2 were classified as low risk (LR), moderate risk (MR), or high risk (HR), respectively. As expected, statistically significant differences were observed among three new combined risk groups (Fig. 5C ).
In addition, we performed a receiver operating characteristic (ROC) curve analysis to compare the discriminative power of LINC01133 expression, LINC01133 combined with drinking status (LINC+Drink), TNM stage, and the combination of the three predictors (LINC+Drink+TNM) for predicting patient survival. Compared with TNM stage, the ROC curves for LINC01133 and LINC+Drink did not illustrate strong separation for OS (area under the ROC curves (AUC): 0.626 vs. 0.614 vs. 0.655, Fig. 5D ) and PFS (AUC: 0.617 vs. 0.591 vs. 0.630, Fig. 5D ). However, LINC+Drink+TNM, which yielded AUC values of 0.679 for OS and 0.651 for PFS, performed best among the four predictors and significantly improved the predictive accuracy compared with that of the TNM stage for OS, but not for PFS (Fig.  5D) . Altogether, these findings suggest that LINC01133 expression combined with drinking status and TNM stage provided greater discriminative power for the prognosis of ESCC. This combined risk model could supply more prognostic information to help oncologists develop effective treatment strategies.
Discussion
Owing to unsatisfactory survival results for patients with resectable ESCC, there is a pressing need to identify key molecular mechanisms underlying the development of this disease in order to improve diagnosis and prognosis [3, 22] . Recent research focusing on lncRNAs has improved our understanding of the complex regulatory mechanisms underlying tumorigenesis and metastasis in human cancers [10] . In ESCC, the dysregulation of some lncRNAs, such as MALAT1 [23, 24] , 91H [25] , HOTAIR [26] , ANRIL [27, 28] , and MEG3 [29, 30] , promotes or inhibits the progression and metastasis of tumors and is closely associated with poor survival [31] . These results confirm that lncRNAs are potential diagnostic and therapeutic biomarkers in ESCC.
In this study, we focused on the novel lncRNA LINC01133, whose role in ESCC was unclear. Our results indicated that LINC01133 expression was significantly reduced in ESCC tissues, as determined by qRT-PCR, and low expression was predictive of poor survival in patients with ESCC, consistent with previous observations [20, 21] . One previous study found that LINC0113 is distributed in the cytoplasm and nucleus based on a FISH assay [20] . LINC01133 may act as pivotal regulator for epigenetic modifications and transcriptional and post-transcriptional processes. Intriguingly, LINC01133 downregulation in our study was positively correlated with large tumors, greater depth of invasion, lymph node metastasis, and advanced TNM stage. Furthermore, a survival analysis in different clinical subgroups indicated that the predictive power of LINC01133 was superior in patients with small tumors, pathological grade I-II, and TNM stage I-II than in patients with large tumors, grade III, and stage III. The clinical results suggested that LINC01133 has a tumor suppressive function in the early stage of ESCC development, and a lack of LINC001133 may induce esophageal squamous cell tumorigenesis.
Increasing reports have established that unhealthy lifestyles (alcohol abuse, tobacco use, and micronutrient deficiency) are risk factors for the initiation and progression of ESCC worldwide [32, 33] . In our study, drinking status, and not smoking status, was significant in OS and PFS by a univariate analysis, but the independent effect of drinking status on the risk of ESCC was not substantiated by a multivariate Cox proportional analysis, consistent with previous results [34, 35] . A potential explanation is that tobacco use impairs the predictive accuracy of drinking status in our cohort, in which only 6.04% of patients were pure drinkers.
Because studies of lncRNAs and environmental risk factors are relatively new, few known lncRNAs (PCGEM1 and lnc-PSD4) are associated with alcohol consumption in human cancer [36, 37] . To our knowledge, lncRNAs correlated with alcohol consumption have not been reported in ESCC. In this study, the expression level of LINC01133 was negatively associated with drinking status. In a stratified analysis, we further found that the discriminative power of LINC01133 was dramatically greater in patients who reported never drinking than in patients who reported ever drinking, and the predictive value of drinking status in patients with low LINC01133 expression was not significant. These results demonstrated that the expression and functions of LINC01133 may be influenced by alcohol. Although alcoholic beverages or ethanol is not classified as a carcinogen, we tentatively hypothesized that acetaldehyde, the metabolite of ethanol and an established carcinogen, regulates the expression and functions of LINC01133 via interfering with epigenetic processes, including DNA repair mechanisms, DNA damage, and histone modifications. This hypothesis warrants further investigation in the near future.
In clinical practice, many oncologists have realized that the TNM staging system alone does not have the optimal predictive value in several human cancers, including ESCC [7, 38, 39] , consistent with our findings. Consequently, additional prognostic biomarkers are required to improve the risk assessment of the TNM staging system. In this regard, we evaluated the impact of LINC01133 or LINC01133 combined with drinking status on patient outcomes. Unfortunately, neither LINC01133 alone nor LINC01133 combined with drinking status had higher sensitivity and specificity than those of TNM stage alone. However, a new risk model based on a combination of LINC01133, drinking status, and TNM stage had the best sensitivity and specificity among the four predictors evaluated, suggesting that this risk model could provide more effective discriminative power for predicting patient survival than the TNM staging system alone. Thus, the simultaneous assessment of LINC01133 expression, 
Conclusion
In summary, our findings indicated that LINC01133 was significantly underexpressed in ESCC. LINC01133 functions as a tumor suppressor and plays a critical role in the early stage of ESCC development. More importantly, our results demonstrated for the first time that drinking status can influence the predictive value of LINC01133 in ESCC. The combination of LINC01133 expression, drinking status, and TNM stage better identified patients with ESCC at high risk after esophagectomy; more aggressive postoperative therapy is recommended for these patients. However, future studies are needed to elucidate the mechanism by which alcohol regulates the biological functions of LINC01133 in ESCC.
